Incannex Healthcare (IXHL) Stock Price, News & Analysis

Company Overview

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Key Stats

• Today's Range: $1.65 to $1.75
• 50-Day Range: $1.63 to $2.94
• 52-Week Range: $1.50 to $8.47
• Volume: 4,789 shs
• Average Volume: 102,130 shs
• Market Capitalization: $30.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IXHL Stock Analysis - Frequently Asked Questions

How have IXHL shares performed this year?

Incannex Healthcare's stock was trading at $4.64 at the beginning of 2024. Since then, IXHL stock has decreased by 62.3% and is now trading at $1.75.
View the best growth stocks for 2024 here.

How were Incannex Healthcare's earnings last quarter?

Incannex Healthcare Inc. (NASDAQ:IXHL) announced its quarterly earnings results on Monday, September, 30th. The company reported ($0.39) EPS for the quarter. The business had revenue of $0.01 million for the quarter.

Who are Incannex Healthcare's major shareholders?

Incannex Healthcare's top institutional investors include Tidal Investments LLC (0.74%) and Virtu Financial LLC (0.06%).

How do I buy shares of Incannex Healthcare?

Shares of IXHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Incannex Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Incannex Healthcare investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Jabil (JBL).

Company Calendar

• Last Earnings: 9/30/2024
• Today: 12/25/2024
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IXHL
• CUSIP: N/A
• CIK: 1873875
• Web: impression.healthcare
• Phone: 425-703-805
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-18,460,000.00
• Net Margins: N/A
• Pretax Margin: -26,887.21%
• Return on Equity: -182.23%
• Return on Assets: -127.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.65
• Quick Ratio: 1.65

Sales & Book Value

• Annual Sales: $86,000.00
• Price / Sales: 359.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.18 per share
• Price / Book: 9.72

Miscellaneous

• Outstanding Shares: 17,643,000
• Free Float: 12,962,000
• Market Cap: $30.88 million
• Optionable: Not Optionable
• Beta: 7.68